---
title: "Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Safety questions"
description: "Safety questions on Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Warnings, and Monitoring. Questions: What are the side effects of Vyndamax? Vyndamax ATTR-ACT trial: how often did Vyndaqel patients stop for side effects? What are the long-term side effects of Vyndamax (ATTR-ACT extension)? What are the contraindications for Vyndamax? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Safety questions

Manufacturer: Pfizer Inc  
Prescribing information: [Vyndaqel and Vyndamax](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685)

## Side effects

<a id="vyndamax-side-effects"></a>

### What are the side effects of Vyndamax?

> “The data reflect exposure of 377 ATTR-CM patients to 20 mg or 80 mg (administered as four 20-mg capsules) of VYNDAQEL administered daily for an average of 24.5 months (ranging from 1 day to 111 months).
>
> Adverse events were assessed from ATTR-CM clinical trials with VYNDAQEL, primarily a 30-month placebo-controlled trial [see Clinical Studies (14)]. The frequency of adverse events in patients treated with VYNDAQEL 20 mg (n=88) or 80 mg (n=176; administered as four 20-mg capsules) was similar to that with placebo (n=177).”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20data%20reflect%20exposure%20of,to%20that%20with%20placebo%20%28n%3D177%29.)

> “There were no known side effects that happened during treatment with VYNDAQEL or VYNDAMAX in people with cardiomyopathy of transthyretin-mediated amyloidosis.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=There%20were%20no%20known%20side,with%20cardiomyopathy%20of%20transthyretin%2Dmediated%20amyloidosis.)

Note: The label's adverse event data come from ATTR-CM trials of VYNDAQEL (tafamidis meglumine), as the first passage states. The second passage is from the FDA-approved Patient Information printed with the label.

<a id="vyndamax-discontinuation"></a>

### Vyndamax ATTR-ACT trial: how often did Vyndaqel patients stop for side effects?

> “In the 30-month placebo-controlled trial, similar proportions of VYNDAQEL-treated patients and placebo-treated patients discontinued the study drug because of an adverse event: 12 (7%), 5 (6%), and 11 (6%) from the VYNDAQEL 80-mg, VYNDAQEL 20-mg, and placebo groups, respectively.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=In%20the%2030%2Dmonth%20placebo%2Dcontrolled%20trial%2C,20%2Dmg%2C%20and%20placebo%20groups%2C%20respectively.)

<a id="vyndamax-long-term-side-effects"></a>

### What are the long-term side effects of Vyndamax (ATTR-ACT extension)?

> “No new safety concerns were observed in patients treated with VYNDAQEL or VYNDAMAX in this analysis. Incidence and types of adverse events were similar to, or lower than, those with pooled VYNDAQEL (80 mg and 20 mg) or placebo in ATTR-ACT<sup>1</sup>”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=No%20new%20safety%20concerns%20were,20%20mg%29%20or%20placebo%20in)

> “The median follow-up was 58.5 months (continuous tafamidis group) and 57.1 months (placebo-to-tafamidis group)<sup>1</sup>”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=The%20median%20follow%2Dup%20was%2058.5,group%29%20and%2057.1%20months%20%28placebo%2Dto%2Dtafamidis)

> “The data reported on the long-term efficacy and safety of tafamidis are from the long-term extension to the ATTR-ACT trial and are not included in the VYNDAQEL/VYNDAMAX prescribing information.”

Source: [VYNDAMAX: Additional Clinical Data | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/additional-data#:~:text=The%20data%20reported%20on%20the,in%20the%20VYNDAQEL%2FVYNDAMAX%20prescribing%20information.)

Note: These passages describe a post hoc, interim analysis of the ATTR-ACT long-term extension, in which patients received VYNDAQEL and then transitioned to VYNDAMAX.

## Warnings

<a id="vyndamax-contraindications"></a>

### What are the contraindications for Vyndamax?

> “4. CONTRAINDICATIONS
>
> None.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=61%22%20in%20white.-,4.%20CONTRAINDICATIONS,None.)

## Safety

<a id="vyndamax-cancer-animal-studies"></a>

### Did Vyndamax (tafamidis) cause cancer in animal studies?

> “There was no evidence of an increased incidence of neoplasia in the transgenic (Tg)-rasH2 mouse following repeated daily administration for 26 weeks at daily doses of 0, 10, 30 or 90 mg/kg. There was no evidence of increased incidence of neoplasia in a 2-year carcinogenicity study in rats at exposures up to 18 times the AUC at the MRHD.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=There%20was%20no%20evidence%20of,the%20AUC%20at%20the%20MRHD.)

> “There was no evidence of mutagenicity or clastogenicity in vitro, and an in vivo rat micronucleus study was negative.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=There%20was%20no%20evidence%20of%20mutagenicity,rat%20micronucleus%20study%20was%20negative.)

<a id="vyndamax-fertility"></a>

### Does Vyndamax (tafamidis) affect fertility?

> “There were no effects of tafamidis meglumine on fertility, reproductive performance, or mating behavior in the rat at any dose.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=There%20were%20no%20effects%20of,the%20rat%20at%20any%20dose.)

Note: This finding is from rat studies of tafamidis meglumine in the Nonclinical Toxicology section of the label.

<a id="vyndamax-qt-prolongation"></a>

### Does Vyndamax prolong the QT interval?

> “At approximately 2.2 times the steady state peak plasma concentration (Cmax) at the recommended dose, tafamidis does not prolong the QTc interval to any clinically relevant extent.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=At%20approximately%202.2%20times%20the,to%20any%20clinically%20relevant%20extent.)

## Monitoring

<a id="vyndamax-thyroid-tests"></a>

### Does Vyndamax affect thyroid function tests?

> “VYNDAQEL and VYNDAMAX may decrease serum concentrations of total thyroxine, without an accompanying change in thyroid stimulating hormone (TSH). This reduction in total thyroxine values is probably the result of reduced thyroxine binding to or displacement from transthyretin (TTR) due to the high binding affinity of tafamidis to the TTR thyroxine receptor. No corresponding clinical findings consistent with hypothyroidism have been observed.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAQEL%20and%20VYNDAMAX%20may%20decrease,with%20hypothyroidism%20have%20been%20observed.)

<a id="vyndamax-lab-monitoring"></a>

### Does Vyndamax require lab monitoring?

> “No lab monitoring required<sup>2</sup>”

Source: [VYNDAMAX: Dosing Information for VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/dosing#:~:text=No%20lab%20monitoring)

Note: The dosing page of the Vyndamax HCP site cites the 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis for this statement.

## Related pages
- [Medical information: Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy)
- [Indication](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/guidelines)
